Regeneron Pharmaceuticals (REGN) Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals has reported Operating Expenses for 18 years, with the latest figure at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 21.56% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $11.3 billion (up 10.1% YoY), and the FY2025 full-year result was $10.8 billion, up 5.42% from the prior year.
• Operating Expenses for Q1 2026 stood at $3.0 billion, down from $3.0 billion in the prior quarter.
• The five-year high for Operating Expenses was $3.0 billion in Q4 2025, with the low at $1.7 billion in Q1 2022.
• Average Operating Expenses over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2025.
• Year-over-year, Operating Expenses dropped 2.46% in 2022 and jumped 31.49% in 2023.
• Tracing REGN's Operating Expenses over 5 years: stood at $2.3 billion in 2022, then climbed by 8.55% to $2.5 billion in 2023, then climbed by 13.72% to $2.8 billion in 2024, then grew by 7.34% to $3.0 billion in 2025, then retreated by 1.39% to $3.0 billion in 2026.
• The last three Operating Expenses figures came in at $3.0 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.

Peer Comparison